Petros Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Petros Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2024.
  • Petros Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 225 %, a 49.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 225 +74.6 +49.4% Sep 30, 2024
Q2 2024 241 +144 +149% Jun 30, 2024
Q1 2024 212 +138 +186% Mar 31, 2024
Q4 2023 177 +112 +173% Dec 31, 2023
Q3 2023 151 +82.8 +122% Sep 30, 2023
Q2 2023 96.7 +13.2 +15.8% Jun 30, 2023
Q1 2023 74.3 -39.3 -34.6% Mar 31, 2023
Q4 2022 64.9 -93.3 -59% Dec 31, 2022
Q3 2022 68 -155 -69.5% Sep 30, 2022
Q2 2022 83.5 Jun 30, 2022
Q1 2022 114 Mar 31, 2022
Q4 2021 158 Dec 31, 2021
Q3 2021 223 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.